Arvinas said it will present new clinical data on its experimental LRRK2 PROTAC degrader at an upcoming movement-disorder meeting. Details were not disclosed, but the update highlights its push in Parkinson’s-related drug development.
published
Arvinas said it will present new clinical data on its experimental LRRK2 PROTAC degrader at an upcoming movement-disorder meeting. Details were not disclosed, but the update highlights its push in Parkinson’s-related drug development.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.